Get the Stockscreener App
3.65
3.95%
-0.15
After Hours:
3.74
0.09
+2.47%
Chromadex Corp stock is traded at $3.65, with a volume of 343.62K.
It is down -3.95% in the last 24 hours and up +5.80% over the past month.
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.
See More
Previous Close:
$3.80
Open:
$3.74
24h Volume:
343.62K
Relative Volume:
0.92
Market Cap:
$275.34M
Revenue:
$83.57M
Net Income/Loss:
$-4.94M
P/E Ratio:
-40.56
EPS:
-0.09
Net Cash Flow:
$6.97M
1W Performance:
-2.41%
1M Performance:
+5.80%
6M Performance:
+4.89%
1Y Performance:
+150.00%
1-Day Range:
$3.62
$3.80
1-Week Range:
$3.62
$3.89
52-Week Range:
$1.25
$4.65
Chromadex Corp Stock (CDXC) Company Profile
Name
Chromadex Corp
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Chromadex Corp Stock (CDXC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Chromadex Corp Stock (CDXC) Latest News
Is ChromaDex (CDXC) Stock Outpacing Its Medical Peers This Year? - MSN
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference - The Bakersfield Californian
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference - StockTitan
Is ChromaDex (CDXC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Two Polish men extradited to NI jailed for drugs offences - Ireland Live
A new experience centre in Bengaluru decodes whisky, gin, and heritage brews of India - Condé Nast Traveller India
Nu Republic launches Cyberstud X2 and Cyberstud X4 Firefly TWS in India - Techlomedia
XLRI JAMSHEDPUR’S PRODZION CLUB HOSTS ITS SECOND PRODUCT SYMPOSIUM: AURORA 2.0 - India Education Diary
Jharkhand News: XLRI Jamshedpur hosts product symposium Aurora - The Jharkhand Story
NI Courts Service awards £85M contract to Canadian IT firm CGI - Belfast Live
Nu Republic Unveils Cyberstud X2 and X4 Firefly Wireless Earbuds - Gadget Bridge
BMS alum Catherine Owen Adams to lead Acadia - BioCentury
Firm appointed on £85m contract to modernise courts system in NI - Belfast Telegraph
'Our NI team is proud to contribute to a program that will impact the present and lay foundation for future innovation' - Belfast News Letter
Check Out Chromadex Corp (CDXC)’s Trade Data Rather Than the Analysts’ Views - SETE News
Northern Ireland courts to receive major IT upgrade - Irish Legal News
Delhi HC upholds Penalty on Custodian for Import of Branded Liquor in Addition to Declared Goods - taxscan.in
ChromaDex appoints new CFO Ozan Pamir - Investing.com
ChromaDex appoints new CFO Ozan Pamir - Investing.com India
County Derry man who operated illegal television streaming service for be sentenced next month - Derry Now
ChromaDex appoints new CFO Ozan Pamir By Investing.com - Investing.com Australia
ChromaDex appoints new CFO Ozan Pamir By Investing.com - Investing.com Canada
ChromaDex Appoints Ozan Pamir As Chief Financial Officer - citybiz
ChromaDex Appoints Ozan Pamir as Chief Financial Officer - StockTitan
Pregabalin: Judge calls for longer drug supply jail terms - BBC.com
'Ludicrous': Derry judge critical of maximum sentence available in wake of case linked to drugs death - Derry Journal
Diageo India opens craft experience home - The Spirits Business
BJP Leader Acquitted in Decade-Old Election Code Case - Town Post
Acer Nitro V 16 AMD Ryzen 7-8845HS NVIDIA GeForce RTX 4060 16GB 1TB SSD - Indiatimes
WINTON GROUP Ltd Invests $597,000 in ChromaDex Co. (NASDAQ:CDXC) - MarketBeat
Insiders own 31% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 42% of the company - Yahoo Finance
ChromaDex (NASDAQ:CDXC) Stock Price Passes Above Two Hundred Day Moving Average of $3.06 - MarketBeat
Wells Pharma to distribute Niagen IV to new clinics By Investing.com - Investing.com Australia
Wells Pharma to distribute Niagen IV to new clinics - Investing.com India
Wells Pharma to distribute Niagen IV to new clinics - Investing.com
Wells Pharma to distribute Niagen IV to new clinics By Investing.com - Investing.com Canada
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics - Morningstar
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics - StockTitan
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions - Business Wire
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions - StockTitan
ChromaDex (NASDAQ:CDXC) Shares Pass Above 200 Day Moving Average of $2.99 - MarketBeat
Top investors say Chromadex Corp (CDXC) ticks everything they need - SETE News
Is Chromadex Corp (CDXC) worth investing in despite its undervalued state? - US Post News
ChromaDex Co. (NASDAQ:CDXC) Director Kristin Patrick Sells 23,000 Shares - Defense World
ChromaDex Co. (NASDAQ:CDXC) Director Kristin Patrick Sells 23,000 Shares - MarketBeat
Chromadex director Kristin Patrick sells $82,110 in company stock - Investing.com
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024 - StockTitan
Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+ - Manchestertimes
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+ - StockTitan
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+ - Yahoo Finance
Chromadex Corp Stock (CDXC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.08%
4.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):